Marianna Sasso
Overview
Explore the profile of Marianna Sasso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I, et al.
Cells
. 2019 Feb;
8(2).
PMID: 30791501
Wound healing fluid that originates from breast surgery increases the aggressiveness of cancer cells that remain after the surgery. We determined the effects of the extent of surgery and tumor-driven...
2.
Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, et al.
Oncotarget
. 2016 Sep;
7(43):69649-69665.
PMID: 27626701
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast...
3.
Bianchi F, Sasso M, Turdo F, Beretta G, Casalini P, Ghirelli C, et al.
J Cell Physiol
. 2015 Feb;
230(11):2661-70.
PMID: 25711523
The tumor-suppressor protein fragile histidine triad (Fhit) exerts its functions in the cytoplasm, although some reports suggest that it may also act in the nucleus. We previously showed that cytosolic...
4.
Plantamura I, Casalini P, Dugnani E, Sasso M, DIppolito E, Tortoreto M, et al.
Mol Oncol
. 2014 Apr;
8(5):968-81.
PMID: 24747080
Triple negative breast cancer (TNBC) is a very aggressive subgroup of breast carcinoma, still lacking specific markers for an effective targeted therapy and with a poorer prognosis compared to other...
5.
Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, et al.
Mol Oncol
. 2012 May;
6(4):458-72.
PMID: 22578566
An increasing body of evidence highlights an intriguing interaction between microRNAs and transcriptional factors involved in determining cell fate, including the well known "genome guardian" p53. Here we show that...
6.
Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello R, de Matteis A, et al.
Breast Cancer Res Treat
. 2011 Apr;
128(1):147-54.
PMID: 21479926
Recent studies have reported the potential clinical utility for metastatic breast cancer (MBC) patients of continuing trastuzumab beyond progression. Based on those results, here the authors have examined the benefits...